Business
Tetra Bio-Pharma Names Vice-President, Clinical Programs and Medical Affairs to Its Leadership Team
Tetra Bio-Pharma Names Vice-President, Clinical Programs and Medical Affairs to Its Leadership Team.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\nORLEANS, Ontario, March 06, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (\"Tetra\" or the \"Corporation\") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery today announced the promotion of Aurelia De Pauw to Vice-President, Clinical Programs and Medical Affairs. In her new role Dr. De Pauw will be responsible for of all clinical operations and relations with the medical community, building Tetra Bio-Pharma’s clinical department and ensuring it continues to meet the highest standards of a pharmaceutical company. She will also drive the Company’s public education initiatives to build and increase awareness about the benefits, cautions, and adverse effects of cannabis-based treatment.\n\n \n \n \n \n \n \n \n \n \n \n \n Aurelia De Pauw, Vice President, Clinical Programs and Medical Affairs\n \n \n \n \n \n \n \n \n\n Aurelia De Pauw holds a master’s degree and Ph.D. in Science from the Gembloux Agro-Bio Tech, University of Liege and the University of Namur, Belgium, followed by a five-year post-doctoral position in the field of stem cell therapy.  After establishing her career in basic sciences and regenerative therapy, she progressed from the laboratory bench to the bedside where she gained an even deeper appreciation of the impact of research on patients and caregivers. Aurelia has extensive experience in numerous therapeutic categories including oncology, drug abuse, endocrinology, dermatology and cardiology.   “Aurelia had an immediate and significant impact since she joined Tetra last year and we are excited to entrust her with greater responsibility as we build on our medical affairs and clinical programs,” said Tetra Bio-Pharma CEO and CSO, Dr. Guy Chamberland. “What is most impressive about Dr. De Pauw is her drive to be part of the transformational process that happens when a drug is discovered, approved and then impacts the patients’ life. This is exactly what Tetra is all about.” “I am proud of the confidence shown in me by Tetra Bio-Pharma’s leadership team and appreciate their support since I joined the Company as Director of Clinical Programs,” said Aurelia De Pauw.  “I believe that cannabinoid derived-drugs have the potential to offer patients new therapeutic altern...